Abstract
Neonatal seizures can be classified as tonic, clonic, myoclonic, and subtle. A clinical diagnosis is not easy as seizures are usually subtle in neonates. In the majority of newborn infants seizures are subclinical. On the other hand, not all abnormal movements identified by clinicians as clinical seizures are accompanied by electroencephalographic seizure discharges in the EEG. Precise incidence is difficult to delineate and depends on study population and criteria used for diagnosis of seizures. Controversy exists as to whether neonatal seizures themselves cause damage to the developing brain, or if the damage is primarily due to the underlying cause of the seizures. As a result of this controversy there is ongoing discussion whether all seizures (both clinical and subclinical) should be treated. In addition, when (sub)clinical seizures are treated, there is no consensus about the most appropriate treatment for neonatal seizures and how to assess the efficacy of treatment.
Current therapeutic options to treat neonatal seizures (i.e. primarily first-generation antiepileptic drugs [AEDs]) are relatively ineffective. In practice, phenobarbital still remains the drug of first choice for EEG confirmed or suspected seizures. Benzodiazepines are also used in (phenobarbital) refractory cases. Several (small) studies indicate that lidocaine is an effective drug for refractory seizures as second- or third-line treatment. Although data are scarce, some AEDs with a wide acceptance in adult and pediatric neurology practice are being used to treat neonatal seizures (i.e. second-generation AEDs). These drugs are chemically different from all first-generation AEDs and they have an effect on other pathways so they provide new pharmacological targets for controlling seizures in newborns. Levetiracetam, topiramate, felbamate, bumetanide, lamotrigine and vigabatrin are examples of these second-generation AEDs.
There is an urgent need for prospective, randomized, controlled trials to assess the efficacy and safety of these second-generation AEDs in neonates.
The aim of this review is to provide an overview of the current knowledge of diagnosis, the effect on brain injury, and the treatment of neonatal seizures.
Similar content being viewed by others
References
Volpe JJ. Neurology of the newborn. 5th ed. Philadelphia: Saunders Elsevier; 2008.
Ronen GM, Penney S, Andrews W. The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. J Pediatr. 1999;134(1):71–5.
Schmitt B, Baumgartner M, Mills PB, et al. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol. 2010;52(7):e133–42.
Hoffmann GF, Schmitt B, Windfuhr M, et al. Pyridoxal 5′-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis. 2007;30(1):96–9.
Lanska MJ, Lanska DJ, Baumann RJ, et al. A population-based study of neonatal seizures in Fayette County, Kentucky. Neurology. 1995;45(4):724–32.
Saliba RM, Annegers JF, Waller DK, et al. Incidence of neonatal seizures in Harris County, Texas, 1992–1994. Am J Epidemiol. 1999;150(7):763–9.
Boylan GB, Rennie JM, Pressler RM, et al. Phenobarbitone, neonatal seizures, and video-EEG. Arch Dis Child Fetal Neonatal Ed. 2002;86(3):F165–70.
Clancy RR, Legido A, Lewis D. Occult neonatal seizures. Epilepsia. 1988;29(3):256–61.
Mizrahi EM, Kellaway P. Characterization and classification of neonatal seizures. Neurology. 1987;37(12):1837–44.
Scher MS, Alvin J, Gaus L, et al. Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatr Neurol. 2003;28(4):277–80.
Glass HC, Sullivan JE. Neonatal seizures. Curr Treat Options Neurol. 2009;11(6):405–13.
Booth D, Evans DJ. Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev 2004; (4): CD004218.
Vento M, de Vries LS, Alberola A, et al. Approach to seizures in the neonatal period: a European perspective. Acta Paediatr. 2010;99(4):497–501.
Volpe JJ. Neonatal seizures: current concepts and revised classification. Pediatrics. 1989;84(3):422–8.
Danner R, Shewmon DA, Sherman MP. Seizures in an atelencephalic infant. Is the cortex essential for neonatal seizures? Arch Neurol. 1985;42(10):1014–6.
Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999;341(7):485–9.
Clancy RR. Prolonged electroencephalogram monitoring for seizures and their treatment. Clin Perinatol. 2006;33(3):649–65. vi.
Lombroso CT, Holmes G. Value of the EEG in neonatal seizures. J Epilepsy. 1993;1(6):39–70.
Clancy RR. The contribution of EEG to the understanding of neonatal seizures. Epilepsia. 1996;37(Suppl. 1):S52–9.
Khan O, Chang E, Cipriani C, et al. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol. 2011;44(4):265–9.
Patrizi S, Holmes GL, Orzalesi M, et al. Neonatal seizures: characteristics of EEG ictal activity in preterm and fullterm infants. Brain Dev. 2003;25(6):427–37.
Shellhaas RA, Clancy RR. Characterization of neonatal seizures by conventional EEG and single-channel EEG. Clin Neurophysiol. 2007;118(10):2156–61.
Clancy RR, Legido A. The exact ictal and interictal duration of electroencephalographic neonatal seizures. Epilepsia. 1987;28(5):537–41.
McBride MC, Laroia N, Guillet R. Electrographic seizures in neonates correlate with poor neurodevelopmental outcome. Neurology. 2000;55(4):506–13.
Oliveira AJ, Nunes ML, Haertel LM, et al. Duration of rhythmic EEG patterns in neonates: new evidence for clinical and prognostic significance of brief rhythmic discharges. Clin Neurophysiol. 2000;111(9):1646–53.
Scher MS, Hamid MY, Steppe DA, et al. Ictal and interictal electrographic seizure durations in preterm and term neonates. Epilepsia. 1993;34(2):284–8.
Shewmon DA. What is a neonatal seizure? Problems in definition and quantification for investigative and clinical purposes. J Clin Neurophysiol. 1990;7(3):315–68.
Murray DM, Boylan GB, Ali I, et al. Defining the gap between electrographic seizure burden, clinical expression, and staff recognition of neonatal seizures. Arch Dis Child Fetal Neonatal Ed 2008;93(3):F187–91.
Maynard D, Prior PF, Scott DF. Device for continuous monitoring of cerebral activity in resuscitated patients. BMJ. 1969;4(682):545–6.
Hellstrom-Westas L, Rosen I. Continuous brain-function monitoring: state of the art in clinical practice. Semin Fetal Neonatal Med. 2006;11(6):503–11.
Toet MC, van Rooij LG, de Vries LS. The use of amplitude integrated electroencephalography for assessing neonatal neurologic injury. Clin Perinatol. 2008;35(4):665–78.
Hellstrom-Westas L, Rosen I. Amplitude-integrated electroencephalogram in newborn infants for clinical and research purposes. Acta Paediatr. 2002;91(10):1028–30.
Spitzmiller RE, Phillips T, Meinzen-Derr J, et al. Amplitude-integrated EEG is useful in predicting neurodevelopmental outcome in full-term infants with hypoxic-ischemic encephalopathy: a meta-analysis. J Child Neurol. 2007;22(9):1069–78.
Hellstrom-Westas L, Rosen I, Swenningsen NW. Silent seizures in sick infants in early life: diagnosis by continuous cerebral function monitoring. Acta Paediatr Scand. 1985;74(5):741–8.
Toet MC, van der Meij W, de Vries LS, et al. Comparison between simultaneously recorded amplitude integrated electroencephalogram (cerebral function monitor) and standard electroencephalogram in neonates. Pediatrics. 2002;109(5):772–9.
Shany E, Khvatskin S, Golan A, et al. Amplitude-integrated electroencephalography: a tool for monitoring silent seizures in neonates. Pediatr Neurol. 2006;34(3):194–9.
Shah DK, Mackay MT, Lavery S, et al. Accuracy of bedside electroencephalographic monitoring in comparison with simultaneous continuous conventional electroencephalography for seizure detection in term infants. Pediatrics. 2008;121(6):1146–54.
Navakatikyan MA, Colditz PB, Burke CJ, et al. Seizure detection algorithm for neonates based on wave-sequence analysis. Clin Neurophysiol. 2006;117(6):1190–203.
Lavery S, Shah DK, Hunt RW, et al. Single versus bihemispheric amplitude-integrated electroencephalography in relation to cerebral injury and outcome in the term encephalopathic infant. J Paediatr Child Health. 2008;44(5):285–90.
Rennie JM, Chorley G, Boylan GB, et al. Non-expert use of the cerebral function monitor for neonatal seizure detection. Arch Dis Child Fetal Neonatal Ed. 2004;89(1):F37–40.
Hellstrom-Westas L. Comparison between tape-recorded and amplitude-integrated EEG monitoring in sick newborn infants. Acta Paediatr. 1992;81(10):812–9.
Shellhaas RA, Soaita AI, Clancy RR. Sensitivity of amplitude-integrated electroencephalography for neonatal seizure detection. Pediatrics. 2007;120(4):770–7.
Silverstein FS, Jensen FE. Neonatal seizures. Ann Neurol. 2007;62(2):112–20.
Levene M. The clinical conundrum of neonatal seizures. Arch Dis Child Fetal Neonatal Ed. 2002;86(2):F75–7.
Miller SP, Weiss J, Barnwell A, et al. Seizure-associated brain injury in term newborns with perinatal asphyxia. Neurology. 2002;58(4):542–8.
van Rooij LG, Toet MC, van Huffelen AC, et al. Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial. Pediatrics. 2010;125(2):e358–66.
Wusthoff CJ, Dlugos DJ, Gutierrez-Colina A, et al. Electrographic seizures during therapeutic hypothermia for neonatal hypoxic-ischemic encephalopathy. J Child Neurol. 2011;26(6):724–8.
Glass HC, Nash KB, Bonifacio SL, et al. Seizures and magnetic resonance imaging-detected brain injury in newborns cooled for hypoxic-ischemic encephalopathy. J Pediatr. 2011;159(5):731–5.
Bittigau P, Sifringer M, Genz K, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA. 2002;99(23):15089–94.
Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci. 2003;993:103–14.
Ikonomidou C, Bittigau P, Koch C, et al. Neurotransmitters and apoptosis in the developing brain. Biochem Pharmacol. 2001;62(4):401–5.
Clancy RR. The newborn drug development initiative workshop: summary proceedings from the neurology group on neonatal seizures. Clin Ther. 2006;28(9):1342–52.
Bartha AI, Shen J, Katz KH, et al. Neonatal seizures: multicenter variability in current treatment practices. Pediatr Neurol. 2007;37(2):85–90.
Carmo KB, Barr P. Drug treatment of neonatal seizures by neonatologists and paediatric neurologists. J Paediatr Child Health. 2005;41(7):313–6.
Glier C, Dzietko M, Bittigau P, et al. Therapeutic doses of topiramate are not toxic to the developing rat brain. Exp Neurol. 2004;187(2):403–9.
Gilman JT, Gal P, Duchowny MS, et al. Rapid sequential phenobarbital treatment of neonatal seizures. Pediatrics. 1989;83(5):674–8.
Van Orman CB, Darwish HZ. Efficacy of phenobarbital in neonatal seizures. Can J Neurol Sci. 1985;12(2):95–9.
Painter MJ, Pippenger C, MacDonald H, et al. Phenobarbital and diphenylhydantoin levels in neonates with seizures. J Pediatr. 1978;92(2):315–9.
Barks JD, Liu YQ, Shangguan Y, et al. Phenobarbital augments hypothermic neuroprotection. Pediatr Res. 2010;67(5):532–7.
Grasela TH Jr, Donn SM. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev Pharmacol Ther. 1985;8(6):374–83.
Castro C Jr, Hernandez Borges AA, Domenech ME, et al. Midazolam in neonatal seizures with no response to phenobarbital. Neurology. 2005;64(5):876–9.
Boylan GB, Rennie JM, Chorley G, et al. Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study. Neurology. 2004;62(3):486–8.
Shany E, Benzaqen O, Watemberg N. Comparison of continuous drip of midazolam or lidocaine in the treatment of intractable neonatal seizures. J Child Neurol. 2007;22(3):255–9.
Yamamoto H, Aihara M, Niijima S, et al. Treatments with midazolam and lidocaine for status epilepticus in neonates. Brain Dev. 2007;29(9):559–64.
van Leuven K, Groenendaal F, Toet MC, et al. Midazolam and amplitude-integrated EEG in asphyxiated full-term neonates. Acta Paediatr. 2004;93(9):1221–7.
Andre M, Boutroy MJ, Dubruc C, et al. Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures. Eur J Clin Pharmacol. 1986;30(5):585–9.
Hellstrom-Westas L, Westgren U, Rosen I, et al. Lidocaine for treatment of severe seizures in newborn infants: I. Clinical effects and cerebral electrical activity monitoring. Acta Paediatr Scand. 1988;77(1):79–84.
Rey E, Radvanyi-Bouvet MF, Bodiou C, et al. Intravenous lidocaine in the treatment of convulsions in the neonatal period: monitoring plasma levels. Ther Drug Monit. 1990;12(4):316–20.
Radvanyi-Bouvet MF, Torricelli A, Rey E, et al. Effects of lidocaine on seizures in the neonatal period: some electroclinical aspects. In: Wasterlain C, Vert P, editors. Neonatal seizures. New York: Raven Press; 1990. p. 277–85.
Malingre MM, van Rooij LG, Rademaker CM, et al. Development of an optimal lidocaine infusion strategy for neonatal seizures. Eur J Pediatr. 2006;165(9):598–604.
van den Broek MP, Huitema AD, van Hasselt JG, et al. Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures. Clin Pharmacokinet. 2011;50(7):461–9.
van Rooij LG, Toet MC, Rademaker KM, et al. Cardiac arrhythmias in neonates receiving lidocaine as anticonvulsive treatment. Eur J Pediatr. 2004;163(11):637–41.
van den Broek MP, Groenendaal F, Egberts AC, et al. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet. 2010;49(5):277–94.
Silverstein FS, Ferriero DM. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol. 2008;39(2):77–9.
Manthey D, Asimiadou S, Stefovska V, et al. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol. 2005;193(2):497–503.
Krief P, Li K, Maytal J. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age. J Child Neurol. 2008;23(5):582–4.
Meehan AL, Yang X, McAdams BD, et al. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J Neurophysiol. 2011;106(3):1227–39.
Kuzniecky R, Pan J, Burns A, et al. Levetiracetam has no acute effects on brain gamma-aminobutyric acid levels. Epilepsy Behav. 2008;12(2):242–4.
Poulain P, Margineanu DG. Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones. Neuropharmacology. 2002;42(3):346–52.
Mazarati AM, Baldwin R, Klitgaard H, et al. Anticonvulsant effects of levetiracetam and levetiracetam–diazepam combinations in experimental status epilepticus. Epilepsy Res. 2004;58(2–3):167–74.
Merhar SL, Schibler KR, Sherwin CM, et al. Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr. 2011;159(1):152–4.
Angehagen M, Ben-Menachem E, Ronnback L, et al. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res. 2003;28(2):333–40.
Schubert S, Brandl U, Brodhun M, et al. Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res. 2005;1058(1–2):129–36.
Zhao Q, Hu Y, Holmes GL. Effect of topiramate on cognitive function and activity level following neonatal seizures. Epilepsy Behav. 2005;6(4):529–36.
Glass HC, Poulin C, Shevell MI. Topiramate for the treatment of neonatal seizures. Pediatr Neurol. 2011;44(6):439–42.
Novotny E, Renfroe B, Yardi N, et al. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology. 2010;74(9):714–20.
Filippi L, la Marca G, Fiorini P, et al. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia. 2009;50(11):2355–61.
Filippi L, Poggi C, la Marca G, et al. Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study. J Pediatr. 2010;157(3):361–6.
Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–76.
Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-d-aspartate and gamma-aminobutyric acidA receptors. Ann Neurol. 1994;35(2):229–34.
Wasterlain CG, Adams LM, Hattori H, et al. Felbamate reduces hypoxic-ischemic brain damage in vivo. Eur J Pharmacol. 1992;212(2–3):275–8.
Laroia N, Guillet R, McBride M. Felbamate in term infants with hypoxic ischemic encephalopathy. J Pediatr Neurology. 2007;5:301–4.
Adusumalli VE, Yang JT, Wong KK, et al. Felbamate pharmacokinetics in the rat, rabbit, and dog. Drug Metab Dispos. 1991;19(6):1116–25.
Adusumalli VE, Wichmann JK, Kucharczyk N, et al. Distribution of the anticonvulsant felbamate to cerebrospinal fluid and brain tissue of adult and neonatal rats. Drug Metab Dispos. 1993;21(6):1079–85.
Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf. 1999;21(3):225–39.
Payne JA, Rivera C, Voipio J, et al. Cation-chloride co-transporters in neuronal communication, development and trauma. Trends Neurosci. 2003;26(4):199–206.
Fukuda A. Diuretic soothes seizures in newborns. Nat Med. 2005;11(11):1153–4.
Kahle KT, Staley KJ. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures. Neurosurg Focus. 2008;25(3):E22.
Dzhala VI, Talos DM, Sdrulla DA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med. 2005;11(11):1205–13.
Pond BB, Berglund K, Kuner T, et al. The chloride transporter Na(+)-K(+)-Cl− cotransporter isoform-1 contributes to intracellular chloride increases after in vitro ischemia. J Neurosci. 2006;26(5):1396–406.
Dzhala VI, Brumback AC, Staley KJ. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. Ann Neurol. 2008;63(2):222–35.
Choi H, Morrell MJ. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin Pharmacother. 2003;4(2):243–51.
Messenheimer J. Efficacy and safety of lamotrigine in pediatric patients. J Child Neurol. 2002;17(Suppl. 2):2S34–42.
Barr PA, Buettiker VE, Antony JH. Efficacy of lamotrigine in refractory neonatal seizures. Pediatr Neurol. 1999;20(2):161–3.
Messenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf. 2000;22(4):303–12.
Morris RG, Black AB, Harris AL, et al. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol. 1998;46(6):547–51.
Metcalf BW. Inhibitors of GABA metabolism. Biochem Pharmacol. 1979;28(11):1705–12.
Haegele KD, Schechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther. 1986;40(5):581–6.
Baxter PS, Gardner-Medwin D, Barwick DD, et al. Vigabatrin monotherapy in resistant neonatal seizures. Seizure. 1995;4(1):57–9.
Vauzelle-Kervroedan F, Rey E, Pons G, et al. Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. Br J Clin Pharmacol. 1996;42(6):779–81.
Jammoul F, Wang Q, Nabbout R, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol. 2009;65(1):98–107.
Wild JM, Chiron C, Ahn H, et al. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs. 2009;23(11):965–82.
Herranz JL, Arteaga R, Farr IN, et al. Dose-response study of vigabatrin in children with refractory epilepsy. J Child Neurol 1991; Suppl. 2: S45-51.
Porro GL, Wittebol-Post D. Impairment of peripheral vision and its measurement. In: Bax M, Dutton G, editors. Visual impairment in children due to damage in the brain. Cambridge: Mc Keith Press; 2010. p. 85–97.
Van den Broek MP, Groenendaal F, Toet MC, et al. Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia. Clin Pharmacokinet. 2012;51:671–9.
Van den Broek MP, Rademaker CM, van Straaten HL, et al. Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing. Arch Dis Child Fetal Neonatal Ed (in press).
Acknowledgements
Linda van Rooij and Marcel van den Broek contributed equally to this article. No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van Rooij, L.G.M., van den Broek, M.P.H., Rademaker, C.M.A. et al. Clinical Management of Seizures in Newborns. Pediatr Drugs 15, 9–18 (2013). https://doi.org/10.1007/s40272-012-0005-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-012-0005-1